On May 16, the pharmaceutical network of nine medicines is only "adult edition" no "children's edition", thousands of hope, including erythromycin in the 40 medicine hope to come to children medicine! National health development planning commission released a few days ago "about the second batch of encourage children's medicine suggested that the list of public r&d declaration", erythromycin, metformin hydrochloride and omeprazole 40 varieties to encourage application list. The reporter knows that the children's drug "cold range" is expected to burn up quickly, but the development is not as simple as the adult medicine. 

 

In fact, children's day on the same day last year, the national health development planning commission "gave a gift", its "about printing of the first to encourage research and development to declare the children's medicine listing notice. Again this year has not yet arrived, the children's day "gift" and the second batch of encouraging r&d to declare the children's medicine inventory, 40, including such as erythromycin, but not yet registered listed in clinical medicine for children need on the list, in order to solve the current our country children's drugs variety, suitable types and specifications of shortage situation. 

 

Journalists know that the shortage of medicines for children in China is a problem of "old and difficult". Because the market coverage than adult drug narrow, target groups to medication safety requirement is high, the children's medicine appropriate dosage forms and specifications scarce, drug companies, development and production of the problem of insufficient power. 

 

A clinical doctor has joked that the shortage of children's medicines could easily lead doctors to "back the pot" for medical accidents. 

 

Policy favors market expansion 

 

However, there are signs that the "cold range" of children's drugs is expected to burn up quickly, which the industry considers blue. In this case, the government intends to invest hundreds of millions of yuan to support domestic companies in developing children's medicines. Over there, the "second child" brings market expansion. Last year, state development planning commission and other six ministries issued "on the strengthening of the reform and development of children's medical and health services opinion", suggests that the current national about 220 million children, children's drugs is a large market. 

 

Moreover, it is not only encouraging research and development, but also a bias in the patent for new drugs. 

 

Reporter learned that, there are more and more leading drug companies listed on the "idea" of playing children's medicine, in addition to a single main Kang Zhi pharmaceutical drug production sales, children have more than 20 listed companies involved in adult and children's medicines at the same time. But there are some industry observers say, children's medication safety is always the focus, children medicine research and development is not adult medicine changed, a so simple, lack of unified ariations of children in our country at present, this also increased the difficulty of the drug development in certain degree.